Announcements Trials

Browse Landscape

Phase

Phase 2 6 Phase 1 4 Phase 1/2 3 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 95 Carcinoma, Non-Small-Cell Lung 87 Lung Neoplasms 21 Squamous Cell Carcinoma of Head and Neck 19 Melanoma 19 Triple Negative Breast Neoplasms 14 Stomach Neoplasms 13 Breast Neoplasms 13 Neoplasm Metastasis 11 Head and Neck Neoplasms 11 Carcinoma, Renal Cell 11 Endometrial Neoplasms 10 Urinary Bladder Neoplasms 9 Neoplasms 9 Carcinoma 9 Carcinoma, Transitional Cell 7 Carcinoma, Hepatocellular 7 Colorectal Neoplasms 6 Uterine Cervical Neoplasms 4 Prostatic Neoplasms 4 Ovarian Neoplasms 4 Neoplasms by Site 4 Esophageal Neoplasms 4 Cholangiocarcinoma 4 Thoracic Neoplasms 3 Small Cell Lung Carcinoma 3 Skin Neoplasms 3 Respiratory Tract Neoplasms 3 Respiratory Tract Diseases 3 Lung Diseases 3

Interventions

Carboplatin 17 Radiotherapy 13 Paclitaxel 13 Cisplatin 9 Vinorelbine 5 Pemetrexed 5 Gemcitabine 5 Docetaxel 5 Mastectomy, Segmental 4 Gefitinib 4 Bevacizumab 4 Taxes 3 Radiation 3 Etoposide 3 ceritinib 2 shark cartilage extract 1 pembrolizumab 1 pegfilgrastim 1 lorlatinib 1 lazertinib 1 efaproxiral 1 Vindesine 1 Vinblastine 1 Tirapazamine 1 Therapeutics 1 Thalidomide 1 Surgical Procedures, Operative 1 Nivolumab 1 Neoadjuvant Therapy 1 Ipilimumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Adenocarcinoma of Lung × pembrolizumab × Clear all

NCT04339218 2026-01-30

CRYOMUNE

Institut Bergonié

Phase 3 Recruiting

Adenocarcinoma of Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡